Targeting WEE1 Kinase in Cancer

Trends in Pharmacological Sciences

Volumn 37, Issue 10, 2016, Pages 872-881

  Matheson, Christopher J ^a   Backos, Donald S ^a   Reigan, Philip ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

combination therapy; DNA damaging agents; inhibitor; kinase; Wee1

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 4 (2 CHLOROPHENYL) 9 HYDROXYPYRROLO[3,4 C]CARBAZOLE 1,3 (2H,6H) DIONE; 6 (2,6 DICHLOROPHENYL) 2 [4 [2 (DIETHYLAMINO)ETHOXY]ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 BUTYL 4 (2 CHLOROPHENYL) 9 HYDROXYPYRROLO[3,4 C]CARBAZOLE 1,3 (2H,6H) DIONE; 9 HYDROXY 4 PHENYLPYRROLO[3,4 C]CARBAZOLE 1,3(2H,6H) DIONE; ANTINEOPLASTIC AGENT; ATM PROTEIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE 1; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHYL 4 [4 [[2 ALLYL 1 [6 (2 HYDROXYPROPAN 2 YL)PYRIDIN 2 YL] 3 OXO 2,3 DIHYDRO 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]AMINO]PHENYL]PIPERAZINE 1 CARBOXYLATE; MITOMYCIN; PACLITAXEL; PEMETREXED; PHOSPHOTRANSFERASE; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; WEE1 KINASE; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; WEE1 PROTEIN, HUMAN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; G2 PHASE CELL CYCLE CHECKPOINT; HEMATOLOGIC DISEASE; HUMAN; IC50; NAUSEA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; VOMITING; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHILD; DNA REPAIR; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CHILD; DNA REPAIR; DRUG DESIGN; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84978879508     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.06.006     Document Type: Review

References (69)

1. 1 Do, K., et al. Wee1 kinase as a target for cancer therapy. Cell Cycle 12 (2013), 3159–3164.
2. 2 Kastan, M.B., Bartek, J., Cell-cycle checkpoints and cancer. Nature 432 (2004), 316–323.
3. 3 Malumbres, M., Barbacid, M., Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9 (2009), 153–166.
4. 4 Dunphy, W.G., The decision to enter mitosis. Trends Cell Biol. 4 (1994), 202–207.
5. 5 Nurse, P., Universal control mechanism regulating onset of M-phase. Nature 344 (1990), 503–508.
6. 6 Heald, R., et al. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 74 (1993), 463–474.
7. 7 Squire, C.J., et al. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure 13 (2005), 541–550.
8. 8 Booher, R.N., et al. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J. Biol. Chem. 272 (1997), 22300–22306.
9. 9 Lindqvist, A., et al. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J. Cell Biol. 185 (2009), 193–202.
10. 10 Boutros, R., et al. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat. Rev. Cancer 7 (2007), 495–507.
11. 11 O'Farrell, P.H., Triggering the all-or-nothing switch into mitosis. Trends Cell Biol. 11 (2001), 512–519.
12. 12 Matsuoka, S., et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 10389–10394.
13. 13 Jazayeri, A., et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8 (2006), 37–45.
14. 14 Johnson, N., et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol. Cell 35 (2009), 327–339.
15. 15 Chen, T., et al. Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today 17 (2012), 194–202.
16. 16 Bucher, N., Britten, C.D., G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. British Journal of Cancer 98 (2008), 523–528.
17. 17 De Witt Hamer, P.C., et al. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res. 17 (2011), 4200–4207.
18. 18 Kellogg, D.R., Wee1-dependent mechanisms required for coordination of cell growth and cell division. J. Cell Sci. 116 (2003), 4883–4890.
19. 19 Dominguez-Kelly, R., et al. Wee1 controls genomic stability during replication by regulating the Mus81–Eme1 endonuclease. J. Cell Biol. 194 (2011), 567–579.
20. 20 Mahajan, K., et al. H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes. Nat. Struct. Mol. Biol. 19 (2012), 930–937.
21. 21 Masaki, T., et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37 (2003), 534–543.
22. 22 Iorns, E., et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE, 4, 2009, e5120.
23. 23 Magnussen, G.I., et al. High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer, 13, 2013, 288.
24. 24 Mueller, S., et al. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro. Oncol. 16 (2014), 352–360.
25. 25 Mir, S.E., et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18 (2010), 244–257.
26. 26 Music, D., et al. Expression and prognostic value of the WEE1 kinase in gliomas. J. Neurooncol. 127 (2016), 381–389.
27. 27 Harris, P.S., et al. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol. Cancer, 13, 2014, 72.
28. 28 Tibes, R., et al. RNAi screening of the kinome with cytarabine in leukemias. Blood 119 (2012), 2863–2872.
29. 29 Porter, C.C., et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26 (2012), 1266–1276.
30. 30 Magnussen, G.I., et al. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS ONE, 7, 2012, e38254.
31. 31 Slipicevic, A., et al. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol. Oncol 135 (2014), 118–124.
32. 32 Lal, S., et al. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res. 74 (2014), 1128–1140.
33. 33 Backert, S., et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int. J. Cancer 82 (1999), 868–874.
34. 34 Yoshida, T., et al. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann. Oncol. 15 (2004), 252–256.
35. 35 Wu, P., et al. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36 (2015), 422–439.
36. 2 checkpoint abrogator. Cancer Res. 61 (2001), 8211–8217.
37. 37 Panek, R.L., et al. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 283 (1997), 1433–1444.
38. 38 Palmer, B.D., et al. Structure–activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. Bioorg. Med. Chem. Lett. 15 (2005), 1931–1935.
39. 39 Hashimoto, O., et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer, 6, 2006, 292.
40. 40 Hashimoto, O., et al. Inhibition of proteasome-dependent degradation of Wee1 in G2-arrested Hep3B cells by TGF beta 1. Mol. Carcinog 36 (2003), 171–182.
41. 41 Li, J., et al. Wild-type TP53 inhibits G2-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat. Res. 157 (2002), 322–330.
42. 42 Palmer, B.D., et al. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure–activity relationships for chromophore modification and phenyl ring substitution. J. Med. Chem. 49 (2006), 4896–4911.
43. 43 Arora, S., et al. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol. Oncol. 118 (2010), 220–227.
44. 44 Hirai, H., et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 8 (2009), 2992–3000.
45. 45 Metz, J.T., et al. Navigating the kinome. Nat. Chem. Biol. 7 (2011), 200–202.
46. 46 Hirai, H., et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol. Ther. 9 (2010), 514–522.
47. 47 Rajeshkumar, N.V., et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin. Cancer Res. 17 (2011), 2799–2806.
48. 48 Leijen, S., et al. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr. Clin. Pharmacol. 5 (2010), 186–191.
49. 49 Van Linden, A.A., et al. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol. Cancer Ther. 12 (2013), 2675–2684.
50. 50 Kreahling, J.M., et al. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol. Cancer Ther. 11 (2012), 174–182.
51. 51 Guertin, A.D., et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol. Cancer Ther. 12 (2013), 1442–1452.
52. 52 Kreahling, J.M., et al. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS ONE, 8, 2013, e57523.
53. 53 Matheson, C.J., et al. A WEE1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells. ACS Chem. Biol. 11 (2016), 921–930.
54. 54 Smyth, L.A., Collins, I., Measuring and interpreting the selectivity of protein kinase inhibitors. J. Chem. Biol. 2 (2009), 131–151.
55. 55 Luo, Y., Selectivity assessment of kinase inhibitors: strategies and challenges. Curr. Opin. Mol. Ther. 7 (2005), 251–255.
56. 56 Krug, M., Hilgeroth, A., Recent advances in the development of multi-kinase inhibitors. Mini. Rev. Med. Chem. 8 (2008), 1312–1327.
57. 57 Murrow, L.M., et al. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res. Treat. 122 (2010), 347–357.
58. 58 Wang, Y., et al. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol. Ther. 3 (2004), 305–313.
59. 59 Leijen, S., et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. ASCO Meeting Abstracts, 28, 2010, 3067.
60. 60 Schellens, J.H., et al. A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. ASCO Meeting Abstracts, 27, 2009, 3510.
61. 61 Schellens, J.H.M., et al. Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. ASCO Meeting Abstracts, 29, 2011, 3068.
62. 62 Do, K., et al. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J. Clin. Oncol. 33 (2015), 3409–3415.
63. 63 Yarden, R.I., et al. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 30 (2002), 285–289.
64. 64 Caretti, V., et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol. Cancer Ther. 12 (2013), 141–150.
65. 65 Lescarbeau, R.S., et al. Quantitative phosphoproteomics reveals Wee1 kinase as a therapeutic target in a model of proneural glioblastoma. Mol. Cancer Ther. 15 (2016), 1332–1343.
66. 66 Sarcar, B., et al. Targeting radiation-induced G2 checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol. Cancer Ther. 10 (2011), 2405–2414.
67. 67 Pokorny, J.L., et al. The Efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood–brain barrier in glioblastoma. Clin. Cancer Res. 21 (2015), 1916–1924.
68. 68 Lian, G., et al. Filamin a regulates neural progenitor proliferation and cortical size through Wee1-dependent Cdk1 phosphorylation. J. Neurosci. 32 (2012), 7672–7684.
69. 69 Kiviharju-af Hallstrom, T.M., et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 7211–7216.